- Home
- AARD vs SLND Comparison
AARD vs SLND Comparison
Compare AARD & SLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- SLND
- Stock Information
- Founded
- AARD 2017
- SLND 1900
- Country
- AARD United States
- SLND United States
- Employees
- AARD N/A
- SLND N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- SLND Military/Government/Technical
- Sector
- AARD Health Care
- SLND Industrials
- Exchange
- AARD Nasdaq
- SLND Nasdaq
- Market Cap
- AARD 154.9M
- SLND 175.8M
- IPO Year
- AARD 2025
- SLND N/A
- Fundamental
- Price
- AARD $6.93
- SLND $3.17
- Analyst Decision
- AARD Strong Buy
- SLND Strong Buy
- Analyst Count
- AARD 4
- SLND 1
- Target Price
- AARD $31.50
- SLND $5.00
- AVG Volume (30 Days)
- AARD 129.3K
- SLND 38.8K
- Earning Date
- AARD 01-01-0001
- SLND 05-12-2025
- Dividend Yield
- AARD N/A
- SLND N/A
- EPS Growth
- AARD N/A
- SLND N/A
- EPS
- AARD N/A
- SLND N/A
- Revenue
- AARD N/A
- SLND $980,179,000.00
- Revenue This Year
- AARD N/A
- SLND $4.06
- Revenue Next Year
- AARD N/A
- SLND $7.16
- P/E Ratio
- AARD N/A
- SLND N/A
- Revenue Growth
- AARD N/A
- SLND N/A
- 52 Week Low
- AARD $4.88
- SLND $1.85
- 52 Week High
- AARD $19.58
- SLND $5.98
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- SLND 51.94
- Support Level
- AARD N/A
- SLND $3.01
- Resistance Level
- AARD N/A
- SLND $3.22
- Average True Range (ATR)
- AARD 0.00
- SLND 0.17
- MACD
- AARD 0.00
- SLND 0.02
- Stochastic Oscillator
- AARD 0.00
- SLND 76.56
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About SLND Southland Holdings Inc.
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures.